A Randomized, Open-Label, Parallel-Group Clinical Study to Evaluate the Bioavailability and Safety of Subcutaneous SHR-1819 Injection Administered Using Different Injection Devices in Healthy Subjects
Latest Information Update: 09 Dec 2025
At a glance
- Drugs SHR-1819 (Primary)
- Indications Atopic dermatitis
- Focus Pharmacokinetics
- Sponsors Guangdong Hengrui Pharmaceutical
Most Recent Events
- 09 Dec 2025 New trial record